Headlines

Hims & Hers Health Inc. (HIMS) Q4 2025 (USD): Adj. EBITDA 66.3mln (exp. 61.8mln), Revenue 618mln (exp. 619mln), Q1 adj. EBITDA view 35-55mln (exp. 81.7mln), revenue view 600-625mln (exp 653mln).

Newsquawk Staff ·

FY guidance

  • Adj. EBITDA 300-375mln (exp. 366.6mln).
  • Revenue 2.7-2.9bln (exp. 2.74bln).

What it means

Hims & Hers Health Inc. reported Q4 earnings that showed an adjusted EBITDA beat expectations, though revenues fell slightly short. However, the starkly lower guidance for Q1 suggests potential concerns about future growth momentum, likely prompting scrutiny of the company's operational challenges. This could lead to downward pressure on the stock as investors reassess expectations against the broader market context.

Related headlines